World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
93
Citations
39121
World Ranking
10752
National Ranking
5530

Overview

Eric Raymond is affiliated with St. Joseph Hospital in the United States and has contributed extensively to research within medicine and molecular biology, particularly focused on oncology and related biomedical fields.

The scientist's main fields of study include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Key subfields of their research encompass:

  • Oncology
  • Molecular Biology
  • Pulmonary and Respiratory Medicine
  • Epidemiology
  • Cancer Research

The primary topics covered in their work reflect a focus on cancer biology and treatment modalities:

  • Lung Cancer Treatments and Mutations
  • Lung Cancer Research Studies
  • Autophagy in Disease and Therapy
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Cancer, Hypoxia, and Metabolism
  • Cancer Immunotherapy and Biomarkers
  • Neuroendocrine Tumor Research Advances

Eric Raymond has published repeatedly in several scientific journals, with frequent contributions to the following publication venues:

  • Targeted Oncology
  • Cancer Research
  • Journal of Clinical Oncology
  • PLoS ONE
  • European Journal of Cancer

Coauthor collaborations feature several individuals with multiple joint publications, including:

  • Sandrine Faivre
  • Annemilaï Tijeras-Raballand
  • Philippe Halfon
  • Valérie Paradis
  • Eloïne Bestion

Among recent publications, notable works include:

  • "Impact of the COVID-19 Outbreak on the Management of Patients with Cancer," 2020, Targeted Oncology
  • "GNS561, a clinical-stage PPT1 inhibitor, is efficient against hepatocellular carcinoma via modulation of lysosomal functions," 2021, Autophagy
  • "Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib," 2020, PLoS ONE
  • "Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression," 2021, British Journal of Cancer
  • "PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma," 2020, OncoImmunology

Best Publications

  • Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

    Eric Raymond;Laetitia Dahan;Jean Luc Raoul;Yung Jue Bang

  • Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer

    Sandrine Faivre;Catherine Delbaldo;Karina Vera;Caroline Robert

  • Current development of mTOR inhibitors as anticancer agents.

    Sandrine Faivre;Guido Kroemer;Eric Raymond

  • Molecular basis for sunitinib efficacy and future clinical development

    Sandrine Faivre;George Demetri;William Sargent;Eric Raymond

  • mTOR-targeted therapy of cancer with rapamycin derivatives

    S. Vignot;S. Faivre;D. Aguirre;E. Raymond

  • Oxaliplatin: A review of preclinical and clinical studies

    E. Raymond;S. G. Chaney;A. Taamma;E. Cvitkovic

  • Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial

    Ann Lii Cheng;Yoon Koo Kang;Deng Yn Lin;Joong Won Park

  • Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids

    Martyn E. Caplin;E. Baudin;P. Ferolla;P. Filosso

  • Oxaliplatin: mechanism of action and antineoplastic activity.

    E Raymond;S Faivre;J M Woynarowski;S G Chaney

  • Cellular and molecular pharmacology of oxaliplatin.

    Eric Raymond;Sandrine Faivre;Stephen Chaney;Jan Woynarowski

  • Safety and Pharmacokinetics of Escalated Doses of Weekly Intravenous Infusion of CCI-779, a Novel mTOR Inhibitor, in Patients With Cancer

    Eric Raymond;Jérôme Alexandre;Sandrine Faivre;Karina Vera

  • ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas

    R. Garcia-Carbonero;H. Sorbye;E. Baudin;E. Raymond

  • Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy.

    Eric Raymond;Sandrine Faivre;Jean Pierre Armand

  • Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors

    Anne O'Donnell;Sandrine Faivre;Howard A. Burris;Daniel Rea

  • Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer

    A. de Gramont;J. Vignoud;C. Tournigand;C. Louvet

  • Effects of cationic porphyrins as G-quadruplex interactive agents in human tumor cells.

    E Izbicka;R T Wheelhouse;R T Wheelhouse;E Raymond;K K Davidson

  • Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials.

    Laurent Meijer;Eric Raymond

  • Oxaliplatin-induced damage of cellular DNA.

    Jan M. Woynarowski;Sandrine Faivre;Sandrine Faivre;Maryanne C.S. Herzig;Brenda Arnett

  • New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.

    Sandrine Faivre;Siham Djelloul;Eric Raymond

  • Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study

    Sandrine Faivre;Eric Raymond;Eveline Boucher;Jean Douillard

Frequent Co-Authors

Pascal Hammel
Pascal Hammel University of Paris-Saclay
Valérie Paradis
Valérie Paradis Université Paris Cité
Ivan Bièche
Ivan Bièche Institute Curie
Philippe Ruszniewski
Philippe Ruszniewski Université Paris Cité
Anne Couvelard
Anne Couvelard Université Paris Cité
Juan W. Valle
Juan W. Valle University of Manchester
Jean-Luc Raoul
Jean-Luc Raoul Institut de Cancérologie de l'Ouest (ICO)
Jacques Belghiti
Jacques Belghiti Beaujon Hospital
Ahmad Awada
Ahmad Awada Université Libre de Bruxelles
Michel Vidaud
Michel Vidaud Université Paris Cité

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

The field of medicine offers diverse pathways beyond traditional medical school, many of which are accessible through flexible online degree programs. For those seeking a doctoral route, online pharmacist programs provide a pathway to a pharmacy career while allowing you to study remotely.

Aspiring professionals interested in healthcare technology and management might consider a him associate degree online, which can open doors to roles in health information management. This field is growing rapidly, offering strong job prospects and the ability to make a meaningful impact on healthcare systems.

If you are looking for entry into the healthcare field quickly, medical billing and coding classes online can prepare you for essential roles in hospitals, clinics, and insurance companies without the need for a multi-year degree.

For those pursuing advanced clinical practice, completing training through the cheapest np school options can help you become a nurse practitioner. This route offers both flexibility and significant responsibility in patient care.

Best Scientists Citing Eric Raymond

Trending Scientists

Recently Published Articles